Stephen Kovacs, DO
Pulmonary Disease · Erie, PANPI 1467574186
Payments from drug & device makers
Across 524 payments — averaging $991.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$248K
- Johnson & Johnson$193K
- Ethicon Endo-surgery Inc.$38K
- Medical Device Business Services, Inc.$26K
- Auris Health, Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- plus $4K from 29 others
What the payments were for
- Consulting fees$407,34378%
- Speaking & faculty fees$20,4024%
- Travel & lodging$68,64313%
- Food & beverage$23,1144%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 152 | $247,906 |
| Johnson & Johnson(2 entities) | 202 | $193,467 |
| Ethicon Endo-surgery Inc. | 20 | $38,242 |
| Medical Device Business Services, Inc. | 22 | $26,232 |
| Auris Health, Inc. | 3 | $6,099 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $3,721 |
| Galvanize Therapeutics, Inc | 12 | $740 |
| AstraZeneca | 18 | $393 |
| Body Vision Medical Inc. | 6 | $336 |
| Philips North America LLC | 17 | $326 |
| Boston Scientific | 3 | $244 |
| Boehringer Ingelheim | 11 | $228 |
| Broncus Medical | 1 | $177 |
| Pulmonx Corporation | 2 | $171 |
| Amgen | 2 | $146 |
| Imbio Inc. | 1 | $129 |
| Resmed Corp | 3 | $127 |
| Regeneron Healthcare Solutions, Inc. | 6 | $123 |
| Sanofi | 4 | $122 |
| Intuitive Surgical | 1 | $76 |
| Jazz Pharmaceuticals Inc. | 4 | $66 |
| Insmed, Inc. | 4 | $62 |
| Baxter Healthcare | 2 | $45 |
| Grifols USA, LLC | 2 | $39 |
| GSK | 2 | $39 |
| Electromed, Inc. | 1 | $37 |
| Mylan Specialty L.p. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| Novartis | 1 | $25 |
| Harmony Biosciences LLC | 1 | $23 |
| 4dmedical USA Inc | 1 | $22 |
| Viatris Specialty LLC | 1 | $19 |
| Healthmyne, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$219,502
- GALAXY$202,870
- MONARCH$39,517
- GLASSIA$2,312
- TEZSPIRE$250
- ALIYA SYSTEM$216
- CHARTIS CATHETER$150
- PULMONX CHARTIS TABLET CONSOLE$150
- ZEPHYR ENDOBRONCHIAL VALVE$150
- ZEPHYR DELIVERY CATHETER$150
- Imbio Lung Density Analysis$129
- EXALT Model D$124
How this compares
$519,502 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 494 | $387,544 |
| Breo ElliptaFluticasone/Vilanterol | 324 | $148,519 |
| Dupixent PenDupilumab | 30 | $117,605 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $101,133 |
| NucalaMepolizumab | 21 | $77,465 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 76 | $44,499 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $33,401 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $24,329 |
| Spiriva RespimatTiotropium Bromide | 40 | $22,070 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $13,169 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 276 | $7,892 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $6,869 |
| DuleraMometasone/Formoterol | 13 | $6,660 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $39 | $660,098923 claims |
| Grifols USA, LLCProlastin C | $39 | $101,13311 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $228 | $66,570116 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $393 | $42,42185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Erie
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.